Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm
US11826320B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2021 |
| Grant date | Nov 28, 2023 |
| Priority date | — |
| Expiry date | Jul 29, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/006
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides a technology for managing elevated cytokine levels and the risk of cytokine storm in viral infection, exemplified by SARS-CoV-2, the virus that causes COVID-19. A special mixture of cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) is extracted from the flowers and leaves of Cannabis sativa (industrial hemp). The purified oil is packed with a surfactant into small micelles, which considerably increases absorption by the gastrointestinal tract, resulting in higher potency and a more rapid onset of action. Daily treatment of patients infected with SARS-CoV-2 reduces the circulating level of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) by 25 to 50% or more. The level of circulating markers of ongoing inflammation, such as C reactive protein (CRP) and/or erythrocyte sedimentation rate (EST) are also reduced. This lowers the risk that the treated patient will suffer the adverse consequences of a cytokine storm, potentially helping the patient to clear the virus and return to good health.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.